Premium
Sophiris Bio Inc (SPHS)
NASDAQ
Hot Features
Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
Sophiris Bio Receives Positive Feedback from FDA Regarding Phase 3 Localized Prostate Cancer Clinical Trial Design PR Newswire SAN DIEGO and VANCOUVER, British Columbia, Oct. 21, 2019 SAN DIEGO...
Sophiris Bio to Present at the H.C. Wainwright 21st Annual Global Investment Conference PR Newswire SAN DIEGO and VANCOUVER, British Columbia, Aug. 30, 2019 SAN DIEGO and VANCOUVER, British...
Sophiris Bio Announces $4.0 Million Registered Direct Offering PR Newswire SAN DIEGO and VANCOUVER, British Columbia, Aug. 27, 2019 SAN DIEGO and VANCOUVER, British Columbia, Aug. 27, 2019...
Sophiris Bio Receives Positive Feedback from European Medicines Agency Regarding Phase 3 Localized Prostate Cancer Clinical Trial Design Conference call scheduled for today at 9:30 a.m. EDT PR...
Sophiris Bio Reports First Quarter 2019 Financial Results PR Newswire SAN DIEGO and VANCOUVER, British Columbia, May 9, 2019 SAN DIEGO and VANCOUVER, British Columbia, May 9, 2019 /PRNewswire/...
Sophiris Bio to Present at Two Upcoming Investor Conferences PR Newswire SAN DIEGO and VANCOUVER, British Columbia, April 2, 2019 SAN DIEGO and VANCOUVER, British Columbia, April 2, 2019...
Sophiris Bio Reports Fourth Quarter 2018 and Year-end Financial Results and Recent Corporate Highlights PR Newswire SAN DIEGO and VANCOUVER, British Columbia, March 13, 2019 SAN DIEGO and...
Sophiris Bio Provides Updates on Phase 2b Localized Prostate Cancer Trial - Reiterates plans to move to Phase 3 with single administration of topsalysin PR Newswire SAN DIEGO and VANCOUVER...
Sophiris Bio to Present at the Piper Jaffray Healthcare Conference PR Newswire SAN DIEGO and VANCOUVER, British Columbia, Nov. 15, 2018 SAN DIEGO and VANCOUVER, British Columbia, Nov. 15, 2018...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
